07.23.26 -- Why Velocity Is the New CDMO Performance Metric

Learn how focused optimization and coordinated execution helped overcome technical uncertainty and enable faster progression to market readiness.

Regulatory and quality compliance are built into every stage of biologics development, helping ensure consistent manufacturing, faster approvals, and dependable global market access.

New expectations for single-use systems require structured risk assessment and extractables testing. As compliance deadlines near, practical guidance aligns science, knowledge, regulatory readiness.

As biologics manufacturing globalizes, companies must balance cost, capacity, risk, and control when choosing between European and Asian supply bases for clinical and commercial success.

Bioprocess changes require robust comparability strategies that combine risk assessment, advanced analytics, and regulatory expectations to keep biologics safe, effective, and compliant.

A single‑site model reduces handoff risks, speeds timelines, strengthens quality oversight, and unifies development and manufacturing to improve reliability and execution efficiency.

Sterile fill–finish is a critical, tightly regulated stage for biotechs, demanding strong contamination control, smart CDMO selection, and awareness of capacity, scalability, and regulatory hurdles.

Establishing unified component standards through collaborative innovation eliminates unnecessary investment, reduces development timelines, and ensures scalable, patient-centered delivery systems.

The top five common cell line development pitfalls — scalability, stability, complexity, analytics, and tech transfer — can be avoided with experienced partners and integrated, predictive strategies.

Developing new delivery routes is essential for creating more effective treatments. Nanoforming enables new routes to simplify dosing, enhance patient comfort, and reduce healthcare costs.

Proper packing for resin is crucial to prevent issues like cracking or channeling which can lead to process disruptions and product loss.

Explore strategies to improve the performance of IB processes as well as the pros and cons of soluble and insoluble processes: isolating, solubilizing, and properly refolding.

True Annex 1 compliance requires a facility-wide contamination-control culture. Discover how rigorous risk awareness shapes behavior at every touchpoint across a manufacturing environment.